TWI585088B - 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 - Google Patents

作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 Download PDF

Info

Publication number
TWI585088B
TWI585088B TW102119261A TW102119261A TWI585088B TW I585088 B TWI585088 B TW I585088B TW 102119261 A TW102119261 A TW 102119261A TW 102119261 A TW102119261 A TW 102119261A TW I585088 B TWI585088 B TW I585088B
Authority
TW
Taiwan
Prior art keywords
group
compound
cancer
phenyl
imidazo
Prior art date
Application number
TW102119261A
Other languages
English (en)
Chinese (zh)
Other versions
TW201400486A (zh
Inventor
吉川謙次
神子島佳子
武田泰幸
山本裕子
田中亮一
富永裕一
木我真基
濱田義人
Original Assignee
第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一三共股份有限公司 filed Critical 第一三共股份有限公司
Publication of TW201400486A publication Critical patent/TW201400486A/zh
Application granted granted Critical
Publication of TWI585088B publication Critical patent/TWI585088B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW102119261A 2012-06-04 2013-05-31 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 TWI585088B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012127079 2012-06-04

Publications (2)

Publication Number Publication Date
TW201400486A TW201400486A (zh) 2014-01-01
TWI585088B true TWI585088B (zh) 2017-06-01

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102119261A TWI585088B (zh) 2012-06-04 2013-05-31 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物

Country Status (32)

Country Link
US (2) US9187489B2 (OSRAM)
EP (1) EP2857404B1 (OSRAM)
JP (1) JP5814467B2 (OSRAM)
KR (1) KR101781255B1 (OSRAM)
CN (1) CN104520300B (OSRAM)
AU (1) AU2013272701B2 (OSRAM)
BR (1) BR112014029851B1 (OSRAM)
CA (1) CA2874819C (OSRAM)
CO (1) CO7160119A2 (OSRAM)
CY (1) CY1119607T1 (OSRAM)
DK (1) DK2857404T3 (OSRAM)
ES (1) ES2648228T3 (OSRAM)
HR (1) HRP20171724T1 (OSRAM)
HU (1) HUE037221T2 (OSRAM)
IL (1) IL236075A (OSRAM)
IN (1) IN2014MN02497A (OSRAM)
LT (1) LT2857404T (OSRAM)
MX (1) MX357021B (OSRAM)
MY (1) MY170326A (OSRAM)
NO (1) NO2857404T3 (OSRAM)
NZ (1) NZ702574A (OSRAM)
PH (1) PH12014502721B1 (OSRAM)
PL (1) PL2857404T3 (OSRAM)
PT (1) PT2857404T (OSRAM)
RS (1) RS56625B1 (OSRAM)
RU (1) RU2635917C2 (OSRAM)
SG (1) SG11201408052WA (OSRAM)
SI (1) SI2857404T1 (OSRAM)
SM (1) SMT201700539T1 (OSRAM)
TW (1) TWI585088B (OSRAM)
WO (1) WO2013183578A1 (OSRAM)
ZA (1) ZA201408843B (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
KR101853026B1 (ko) 2008-10-22 2018-04-27 어레이 바이오파마 인크. TRK 키나아제 억제제로서 치환된 피라졸로[1,5­a] 피리미딘 화합물
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN105693720B (zh) 2010-05-20 2019-01-18 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
CA2872645A1 (en) 2012-05-30 2013-12-05 Nippon Shinyaku Co., Ltd. Aromatic heterocyclic derivative and pharmaceutical
AU2015238298B2 (en) * 2014-03-27 2019-04-18 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
EA032255B1 (ru) * 2014-03-27 2019-04-30 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-a][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Ros1
EP3134084B1 (en) * 2014-04-25 2021-03-17 Exelixis, Inc. Method of treating lung adenocarcinoma
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
KR20180021745A (ko) 2015-06-01 2018-03-05 록쏘 온콜로지, 인코포레이티드 암을 진단하고 치료하는 방법
US10919875B2 (en) 2015-06-18 2021-02-16 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivatives
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE068971T2 (hu) 2016-04-04 2025-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei
SI3458456T1 (sl) 2016-05-18 2021-04-30 Loxo Oncology, Inc. Priprava (S)-N-(5-((R)-2-(2,5-difluorofenil) pirolidin-1-il) pirazolo (1,5-A) pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CA3055504A1 (en) * 2017-03-14 2018-09-20 Daiichi Sankyo Company, Limited Method for producing 3,6-disubstituted imidazo[1,2-b]pyridazine derivative
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3700576A1 (en) 2017-10-26 2020-09-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
US12077599B2 (en) 2017-11-29 2024-09-03 Seoul National University R&Db Foundation, National Cancer Center Anti-ROS1 antibody and use thereof
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CA3095366A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
EP3827009A4 (en) 2018-07-24 2022-04-27 Taiho Pharmaceutical Co., Ltd. HETEROBICYCLIC COMPOUNDS TO INHIBIT SHP2 ACTIVITY
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN113543852A (zh) * 2019-03-06 2021-10-22 第一三共株式会社 吡咯并吡唑衍生物
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
JP7420403B2 (ja) 2019-05-08 2024-01-23 ティーワイケー メディシンズ インコーポレーテッド キナーゼ阻害剤として使用される化合物およびその応用
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
US20240309007A1 (en) * 2021-07-01 2024-09-19 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
CA3254138A1 (en) * 2022-05-18 2023-11-23 Nuvation Bio Inc. PROCESS FOR THE PRODUCTION OF IMIDAZO[1,2-B]PYRIDAZINE 3,6-DISUBSTITUTES COMPOUNDS
CN114989176B (zh) * 2022-07-08 2024-08-27 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115B (zh) * 2022-08-25 2024-11-08 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
AU2023339247A1 (en) 2022-09-07 2025-03-27 Suzhou Langrui Biopharmaceutical Co., Ltd. Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093475A1 (en) * 2006-06-21 2009-04-09 Olaf Prien Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
AU8664701A (en) 2000-09-01 2002-03-22 Glaxo Group Ltd Oxindole derivatives
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2007533717A (ja) 2004-04-21 2007-11-22 アストラゼネカ アクチボラグ 化合物
WO2006070943A1 (ja) 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
NZ561145A (en) 2005-02-04 2011-02-25 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2006087538A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
CN101208339B (zh) * 2005-08-01 2010-12-29 霍夫曼-拉罗奇有限公司 杂环苄基氨基衍生物,它们的制备以及作为药剂的应用
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20100041662A1 (en) 2006-10-30 2010-02-18 Sandrine Ferrand Heterocyclic compounds as antiinflammatory agents
MX2009004700A (es) * 2006-11-06 2009-05-15 Supergen Inc Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
BRPI0912668A2 (pt) 2008-05-13 2016-01-26 Irm Llc composto e composições como inibidores de quinase
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
WO2012005299A1 (ja) 2010-07-07 2012-01-12 日本新薬株式会社 Rosチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093475A1 (en) * 2006-06-21 2009-04-09 Olaf Prien Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals

Also Published As

Publication number Publication date
ZA201408843B (en) 2016-01-27
KR101781255B1 (ko) 2017-09-22
BR112014029851A2 (pt) 2017-06-27
NO2857404T3 (OSRAM) 2018-01-20
RU2635917C2 (ru) 2017-11-17
JPWO2013183578A1 (ja) 2016-01-28
HUE037221T2 (hu) 2018-08-28
AU2013272701A2 (en) 2015-01-22
LT2857404T (lt) 2017-11-10
JP5814467B2 (ja) 2015-11-17
US20150051190A1 (en) 2015-02-19
SI2857404T1 (sl) 2017-11-30
MX357021B (es) 2018-06-25
CN104520300B (zh) 2016-12-21
CA2874819A1 (en) 2013-12-12
PH12014502721A1 (en) 2015-02-02
US9187489B2 (en) 2015-11-17
US9751887B2 (en) 2017-09-05
SG11201408052WA (en) 2015-01-29
CO7160119A2 (es) 2015-01-15
US20160046639A1 (en) 2016-02-18
RU2014153627A (ru) 2016-08-10
RS56625B1 (sr) 2018-03-30
IL236075A (en) 2017-10-31
WO2013183578A1 (ja) 2013-12-12
HRP20171724T1 (hr) 2018-01-12
ES2648228T3 (es) 2017-12-29
CY1119607T1 (el) 2018-04-04
TW201400486A (zh) 2014-01-01
KR20150014942A (ko) 2015-02-09
IL236075A0 (en) 2015-02-01
EP2857404A4 (en) 2016-01-20
SMT201700539T1 (it) 2018-01-11
HK1207374A1 (en) 2016-01-29
CA2874819C (en) 2017-06-20
CN104520300A (zh) 2015-04-15
AU2013272701A1 (en) 2015-01-15
DK2857404T3 (en) 2017-12-04
PL2857404T3 (pl) 2018-04-30
MX2014014803A (es) 2015-02-12
PT2857404T (pt) 2017-11-23
MY170326A (en) 2019-07-17
AU2013272701B2 (en) 2017-12-21
EP2857404B1 (en) 2017-08-23
IN2014MN02497A (OSRAM) 2015-07-17
PH12014502721B1 (en) 2015-02-02
NZ702574A (en) 2016-07-29
EP2857404A1 (en) 2015-04-08
BR112014029851B1 (pt) 2023-01-03

Similar Documents

Publication Publication Date Title
TWI585088B (zh) 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
CN111285850B (zh) 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
CN108349896B (zh) 作为fgfr抑制剂的杂环化合物
JP6267231B2 (ja) カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール
EP4389738A1 (en) Sos1 inhibitor and use thereof
JP7420403B2 (ja) キナーゼ阻害剤として使用される化合物およびその応用
WO2020200158A1 (zh) 用于治疗癌症的氮杂芳环酰胺衍生物
KR20200135827A (ko) Prmt5 억제제로서 치환된 이미다졸리딘-2-온 유도체
US20240408064A1 (en) Ras inhibitors, compositions and methods of use thereof
EP3694331A1 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP4141003A1 (en) Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof
EP4308096A1 (en) Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
JPWO2018097295A1 (ja) ピリド[3,4−d]ピリミジン誘導体又はその溶媒和物の結晶
RU2806625C2 (ru) Соединения на основе пиразолопиридинона
RU2810113C2 (ru) Новые хинолиновые соединения
EP4644374A1 (en) Naphthylamide compound, and preparation method therefor and use thereof
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors